December 23, 1975. The knock on the door was not loud, but it was persistent. I was in the living room, listening to Prime ...

Energy was relatively muted for the first half of the ‘World Series’ final, though not for the want of trying by gregarious compere Hayley Ellis, with her chipper banter and relatable anecdotes, ...

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused ...

(RTTNews) - RAPT Therapeutics, Inc. (RAPT) said it is terminating zelnecirnon program. Zelnecirnon was being evaluated in two randomized, placebo-controlled Phase 2 clinical trials in asthma and ...

Snowdonia could remove its English name from the national park’s logo after it said that using its Welsh name had been a success. Snowdonia National Park Authority voted to replace Snowdon with ...

RAPT Therapeutics has called it quits on a clinical programme evaluating zelnecirnon (RPT193) in inflammatory disorders following feedback with the US Food and Drug Administration (FDA).

Given this risk, we thought we'd take a look at whether RAPT Therapeutics (NASDAQ:RAPT) shareholders should be worried about its cash burn. For the purpose of this article, we'll define cash burn ...

Roman Polanski’s film An Officer and a Spy is to receive its UK premiere, five years after winning the Grand Jury Prize at the Venice Film Festival, and despite being frozen out of the UK and ...

Kick-off is scheduled for 11:30pm UK time, with the half-time show expected ... The Super Bowl 2025 logo was designed by Tahj Williams, an artist from New Orleans. It is the first time ever ...

Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping development of its drug candidate zelnecirnon due to negative FDA feedback.

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a biotechnology company focused on developing small-molecule drugs for inflammatory diseases and cancer, has recently faced significant challenges in its drug ...